Metabolon Announces First in a Series of New Research Tools

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that it has released mFocus TST™ (Tissue-based Sarcosine Test), a research use only assay that measures the level of sarcosine in a biological sample. Based on biomarkers identified in a study conducted by Metabolon to better understand the metabolic changes associated with prostate cancer progression, the assay is the first available test that reports a biochemistry-based measurement of prostate cancer aggressiveness.